Precision medicine in type 2 diabetes
Authors:
Open Access
- 7 November 2018
- journal article
- review article
- Published by Wiley in Journal of Internal Medicine
- Vol. 285 (1) , 40-48
Abstract
The Precision Medicine Initiative defines precision medicine as ‘an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment and lifestyle for each person’. This approach will facilitate more accurate treatment and prevention strategies in contrast to a one‐size‐fits‐all approach, in which disease treatment and prevention strategies are developed for generalized usage. Diabetes is clearly more heterogeneous than the conventional subclassification into type 1 and type 2 diabetes. Monogenic forms of diabetes like MODY and neonatal diabetes have paved the way for precision medicine in diabetes, as carriers of unique mutations require unique treatment. Diagnosis of diabetes in the past has been dependent upon measuring one metabolite, glucose. By instead including six variables in a clustering analysis, we could break down diabetes into five distinct subgroups, with better prediction of disease progression and outcome. The severe insulin‐resistant diabetes (SIRD) cluster showed the highest risk of kidney disease and highest prevalence of nonalcoholic fatty liver disease, whereas patients in the insulin‐deficient cluster 2 (SIDD) had the highest risk of retinopathy. In the future, this will certainly be improved and expanded by including genetic, epigenetic and other biomarker to allow better prediction of outcome and choice of more precise treatment.Keywords
Funding Information
- Vetenskapsrådet
- European Research Council
- Research Council of Finland
This publication has 57 references indexed in Scilit:
- Diabetes and Pancreatic Exocrine Dysfunction Due to Mutations in the Carboxyl Ester Lipase Gene-Maturity Onset Diabetes of the Young (CEL-MODY)Journal of Biological Chemistry, 2011
- Human Fatty Liver Disease: Old Questions and New InsightsScience, 2011
- Metabolite profiles and the risk of developing diabetesNature Medicine, 2011
- Common variants near ATM are associated with glycemic response to metformin in type 2 diabetesNature Genetics, 2010
- Recessive mutations in the INS gene result in neonatal diabetes through reduced insulin biosynthesisProceedings of the National Academy of Sciences, 2010
- Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetesJournal of Clinical Investigation, 2007
- A Genome-Wide Association Study of Type 2 Diabetes in Finns Detects Multiple Susceptibility VariantsScience, 2007
- Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin actionJournal of Clinical Investigation, 2007
- A genome-wide association study identifies novel risk loci for type 2 diabetesNature, 2007
- Sex-specific, male-line transgenerational responses in humansEuropean Journal of Human Genetics, 2005